Analyst Research and Ratings: Blue Apron Holdings, Inc. (APRN), Conatus Pharmaceuticals Inc. (CNAT)

Blue Apron Holdings, Inc. (NYSE:APRN) tinted loss of -0.63% (-0.01 points) to US$1.58. The volume of 2.63 Million shares climbed down over an trading activity of 3.65 Million shares. EPS ratio determined by looking at last 12 month figures is -0.63. Over the same time span, the stock marked US$4.2 as its best level and the lowest price reached was US$0.65. The corporation has a market cap of US$295.04 Million.

Blue Apron Holdings, Inc. (NYSE:APRN)’s earnings per share has been growing at a 0 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -104.6 percent while most common profitability ratio return on investment (ROI) was -54.1 percent. The company’s institutional ownership is monitored at 26.1 percent. The company’s net profit margin has achieved the current level of -28.6 percent and possesses 35.1 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 0 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 13 think it is Hold. Recently, analysts have updated the overall rating to 2.93. 1 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) is worth US$63.57 Million and has recently fallen -0.48% to US$2.06. The latest exchange of 0.51 Million shares is below its average trading activity of 815.27 Million shares. The day began at US$0 but the price moved to US$0 at one point during the trading and finally capitulating to a session high of US$0. The stock tapped a 52-week high of US$7.95 while the mean 12-month price target for the shares is US$12.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 3.76, and a price to sales ratio of 1.82. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 41.1%. With an institutional ownership near 32.9%, it carries an earnings per share ratio of -0.61.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 1 brokerage firms polled by Factset Research. At present, 1 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 3 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.